Bacteremia
Drug research and approvals for bacteremia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 22, 2026, 50 studies of bacteremia are recruiting on ClinicalTrials.gov, Health Canada has authorized 1 drug trials for it since 2013, and FDA has 0 approved and 1 open orphan designations naming it.
- Recruiting worldwide: 50
- Trials authorized in Canada: 1
- FDA orphan approvals: 0
- EU medicines: 0
- Oral Switch in Bloodstream Infections in Immunocompromised ChildrenNCT07923266 · Phase 4 · Copenhagen University Hospital, Rigshospitalet · starts Nov 9, 2026
- Middle East Study of Infections in Patients With Hematological MalignanciesNCT07900542 · Not reported · Hamad Medical Corporation · starts Sep 15, 2024
- Evaluation of Diagnostic Accuracy and Clinical Performance of the UllCORE Bloodstream Infection (BSI) TestNCT07859852 · Not reported · Deepull Diagnostics S.L. · starts Sep 21, 2026
- Oral Switch in Pediatric Bloodstream InfectionsNCT07791914 · Phase 4 · Ulrikka Nygaard · starts Sep 1, 2026
- Short-Chain Fatty Acids in Lypopolysaccharide-Induced Inflammation and Executive FunctionNCT07713641 · Not applicable · Universitaire Ziekenhuizen KU Leuven · starts Oct 24, 2025
- The Impact of Fast Antimicrobial Sensitivity Testing Tools on Stewardship Antibiotic and Clinical Outcome (ACT-FAST)NCT07491419 · Not applicable · Istituto Clinico Humanitas · starts Mar 19, 2026
- The Per-procedural Antibiotic Prophylaxis in Patients Undergoing Transcatheter Aortic Valve Implantation TrialNCT07442357 · Not applicable · Copenhagen University Hospital, Rigshospitalet · starts Oct 1, 2026
- OxiCLEAR (Oxiris Cytokines and Endotoxin Adsorption Rate) StudyNCT07419802 · Not reported · Pauls Stradins Clinical University Hospital · starts Mar 1, 2026
- Clinical Efectiveness of a Multiplex PCR-Based Rapid Diagnostic Method in Bloodstream InfectionsNCT07408544 · Not reported · Istanbul Medipol University Hospital · starts Jan 1, 2026
Approved 7
- DaptomycinCell membrane inhibitor
- LinezolidBacterial 70S ribosome inhibitor
- MeropenemBacterial penicillin-binding protein inhibitor
- Ceftobiprole medocaril free acidPenicillin-binding protein 1 inhibitor
- Polymyxin bCell outer membrane inhibitor
- Penicillin vBacterial penicillin-binding protein inhibitor
- CefepimeBacterial penicillin-binding protein inhibitor
Phase 3 9
- VancomycinPeptidoglycan inhibitor
- CefazolinBacterial penicillin-binding protein inhibitor
- OxacillinPenicillin-binding protein inhibitor
- Penicillin gBacterial penicillin-binding protein inhibitor
- TelavancinCell outer membrane inhibitor
- ChlorhexidineCell membrane inhibitor
- DicloxacillinPenicillin-binding protein inhibitor
- TemocillinBacterial penicillin-binding protein inhibitor
- Alcohol
Phase 2 9
- DalbavancinPeptidoglycan inhibitor
- NeomycinBacterial 70S ribosome inhibitor
- TigecyclineBacterial 70S ribosome inhibitor
- HeparinAntithrombin-III activator
- AmoxicillinBacterial penicillin-binding protein inhibitor
- NafcillinPenicillin-binding protein inhibitor
- NystatinErgosterol sequestering agent
- ColistinCell outer membrane inhibitor
- AcetylcysteineGlutathione precursor
Phase 1 or earlier 1
How its trials ended
317 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 86 whose ending is known, 37% met their primary endpoint, 7% missed it and 56% stopped early.
- Completed, result not reported13141%
- Ongoing6119%
- Status unknown3912%
- Met its primary endpoint3210%
- Stopped: other or unclear268%
- Stopped: enrollment or feasibility113%
- Stopped: lack of efficacy72%
- Missed its primary endpoint62%
- Stopped: sponsor or business decision21%
- Stopped: safety1<1%
- Stopped: funding1<1%
| Authorized | Trial | Sponsor | Status |
|---|---|---|---|
| Jan 4, 2022 | Combination cefazolin with ertapenem for methicillin-susceptible staphylococcus aureus bacteremia (CERT)Ertapenem | Research Institute of The McGill University Health Centre | Ongoing |
| Date | Drug | Sponsor | Status |
|---|---|---|---|
| Jun 13, 2001 | Staphylococcal immunoglobulin (human)Reduction (prevention) of nosocomial bacteremia caused by staphylococci in very low birth weight infants. | Inhibitex, Inc. | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA